Phase 2 N=56 Anemia in Heart Failure With a Preserved Ejection Fraction (HFPEF)
Anemia
Primary: Change in Left Ventricular End-diastolic Volume — -6; -4 mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=90 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
Phase 4 N=324 Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
Chronic Heart Failure With Preserved Systolic Function
Primary: Effect of Dapagliflozin, as Compared With Placebo, on Heart Failure Related Health Status Using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Summary…
Phase 4 N=55 Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF
Heart Failure, Diastolic · Diastolic Heart Failure · Hypertension
Primary: Coronary Flow Reserve — 2.64; 2.65; 2.06 ratio
Phase 2 N=28 Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction
Heart Disease · Heart Failure With Preserved Ejection Fraction · Exercise Intolerance
Primary: Exercise Pulmonary Capillary Wedge Pressure (PCWP) — 19.0; 28.0 mm Hg — p=0.0003
Phase 2 N=26 Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Change in Pulmonary Capillary Wedge Pressure During Exercise — -1; -4 millimeters of mercury — p=0.002
Phase 3 N=52 Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Heart Failure, Diastolic · Pulmonary Hypertension
Primary: Mean Pulmonary Artery Pressure Measured by Right Heart Catheterization — -2.4; -4.7 mmHG
Phase 4 N=37 Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Plasma N-terminal Proatrial Natriuretic Peptide (NT proANP) — 47.4; 46.4 pg/mL
N/A N=19 High Intensity Interval Exercise in Diastolic Heart Failure
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade
Phase 3 N=504 DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction (HFpEF)
Primary: Change From Baseline in Kansas-City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 16 (Higher Scores Represent Less HF Symptom Frequency and Burden)…
Phase 2 N=44 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Heart Failure · Congestive Heart Failure
Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio
Phase 3 N=6,263 Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
Heart Failure With Preserved Ejection Fraction
Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 512; 610 Participants — p=0.0008
Phase 2 N=31 Interleukin-1 Blockade in HF With Preserved EF
Heart Failure With Normal Ejection Fraction
Primary: Change in Aerobic Exercise Capacity — -0.2; 1.0 ml/kg/min
N/A N=101 Heart Function in Patients Assessed for Sleep Apnoea
Heart Failure With Preserved Ejection Fraction · Sleep Disordered Breathing · Heart Failure With Normal Ejection Fraction
Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
N/A N=602 Heart Failure Optimization Study
Sudden Cardiac Death · Sudden Cardiac Arrest · Heart Failure
Primary: Percentage of Patients With LVEF Recovery at Day 90 and 180 — 222; 0; 0; 0 Participants
Phase 3 N=80 PIE II: Pharmacological Intervention in the Elderly II
Diastolic Heart Failure · Heart Failure, Congestive
Primary: Exercise Intolerance — 13.5; 13.3; 13.6; 13.5 ml/kg/min
Phase 2 N=142 A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Heart Failure With Preserved Ejection Fraction
Primary: Percent of Baseline N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assessed at Week 24 — 108.39; 106.27 percentage of baseline NT-proBNP — p=0.7923
N/A N=52 Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Normal Ejection Fraction
Primary: E/e' (Early Mitral Inflow Doppler Velocity to the Early Diastolic Mitral Annulus Velocity) — 10.4; 9.9 ratio
Phase 2 N=71 Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
Heart Failure
Primary: Change in Left Ventricular End Systolic Volume (ml) — -4.4; -1.2; -3.8 mL
Phase 2 N=15 Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction
Heart Failure
Primary: Cardiorespiratory Fitness — 4.1; 4.0; 5.1; 4.5 ml/kg/min
Phase 2 N=38 Dapagliflozin (DAPA) Effects in HFpEF
Heart Failure With Preserved Ejection Fraction
Primary: Pulmonary Capillary Wedge Pressure (PCWP) at Maximal Exercise — -6.6; -0.4 mmHg — p=0.027
Phase 3 N=2,572 A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
Heart Failure With Preserved Ejection Fraction
Primary: Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12 — 0.8218; 0.9828 Ratio — p=<0.0001
N/A N=71 Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome
Heart Failure
Primary: Carotid-femoral Pulse Wave Velocity — -0.3; 0.4 m/s — p=0.28
N/A N=10 The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Exercise Capacity at 6 Weeks — 659.9; 300.5 seconds — p=0.47
Phase 2 N=35 Heart Failure Polypill at a Safety Net Hospital
Heart Failure With Reduced Ejection Fraction · HIV Infections
Primary: Measured Adherence to GDMT by Pill Count — 74.6; 83.3 adherence ratio expressed in %
Phase 3 N=5,988 EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
Heart Failure
Primary: Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) — 8.67; 6.86 Patients with event/100 pt-yrs at risk…
Phase 4 N=50 BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart Failure With Preserved Ejection Fraction · Hypertension
Primary: Difference in Home Systolic Blood Pressure — 130.7; 134.5 mm Hg — p=0.017
Phase 3 N=30 Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial
Congestive Heart Failure · Heart Failure, Left-Sided · Left-Sided Heart Failure
Primary: Change in 20 Watt Exercise Pulmonary Vascular Resistance (PVR) — -0.6; 0.1 wood units — p=0.003
N/A N=335 Heart Failure Study: The Atlanta Cardiomyopathy Consortium
Heart Failure
Primary: Death, Heart Transplant, Left Ventricular Assist Device Implantation — 35 participants